This gene panel provides oncologists with clinically actionable insights from individual patients’ tumor tissue. The detailed genetic information obtained through this gene panel testing allows oncologists to make informed treatment decisions.

This gene panel includes common and rare gene fusions and identifies novel fusion partners. This aspect of the gene panel testing is particularly valuable as it expands the understanding of fusion events in cancer, potentially uncovering new therapeutic targets or diagnostic markers that were previously unknown.

This gene panel goes beyond genetic alterations by incorporating immunotherapy biomarkers such as tumor mutational burden (TMB), microsatellite instability (MSI), and programmed death-ligand 1 (PD-L1) expression. These biomarkers play a crucial role in predicting response to immune checkpoint inhibitors, a cancer treatment that has shown remarkable success in certain patients.

This gene panel holds significant research value besides its clinical applications. The panel covers well-known oncogenic driver mutations and rare and novel fusions, providing researchers with valuable data for studying cancer development and progression mechanisms.

Our Cancer Gene Panel thoroughly assesses clinically relevant genes, ensuring accurate and reliable results.

We utilize cutting-edge next generation sequencing technology to deliver precise and detailed genetic information.

Our team of experienced genetic counselors and healthcare professionals will guide you through the testing process, answer your questions, and help you understand the implications of the results.

We adhere to strict privacy protocols and maintain the confidentiality of your genetic information.